ストックスクリーナーアプリを入手
164.84
0.46%
-0.76
Glaukos Corp (GKOS) 最新ニュース
Mizuho lifts target for Glaukos stock to USD 190.00 - ad-hoc-news.de
Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery - Glance by Eyes On Eyecare
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
Midday Stock Roundup: loanDepot Shares Continue Falling - Orange County Business Journal
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - TradingView
Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes - Glance by Eyes On Eyecare
Enrollment Complete in Glaukos Study of the PRESERFLO MicroShunt - Medical Product Outsourcing
Midday Stock Roundup: Karman Slips - Orange County Business Journal
GKOS Maintained by BTIG -- Price Target Raised to $205 - GuruFocus
(GKOS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Glaukos: Steep Premium For New Therapies And Growth (NYSE:GKOS) - Seeking Alpha
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada
Glaukos: The Second J-Code Rewrites The Risk Math - Seeking Alpha
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - The Globe and Mail
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Barchart.com
Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i - GuruFocus
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Zacks Investment Research
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Benzinga
Glaukos Reports Positive Phase 4 Results for iDose TR - Orange County Business Journal
Glaukos' iDose TR meets primary goal in phase 4 trial - Seeking Alpha
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Zacks Investment Research
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Yahoo Finance
Why is Glaukos stock climbing today? - Investing.com
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - BioSpace
Glaukos licenses rights to Revopsis’ RO-104 for retinal diseases - BioWorld News
Glaukos licenses preclinical tri-specific retinal biologic RO-104 from RevOpsis - AllSci
Glaukos Says Phase 4 Trial of iDose TR Meets Primary Efficacy Endpoint - marketscreener.com
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - Yahoo Finance
Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics for Biologic to Treat Retinal Diseases - VisionMonday.com
Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics for Biologic to Treat Retinal Diseases - VisionMonday.com
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal - Benzinga
Glaukos (GKOS) Shares Fall 13% Despite Positive Epioxa Trial Res - GuruFocus
Glaukos' Epioxa maintains corneal flattening and visual gains through 3 years in keratoconus - Ophthalmology Times
Will Three-Year Epioxa Data in Keratoconus Shift Glaukos' (GKOS) Corneal Portfolio Narrative? - Yahoo Finance
Glaukos slips as insider selling overshadows positive trial data for eye therapy - TradingView
Eli Lilly, Glaukos among market cap stock movers on Thursday - Investing.com
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases - BioSpace
Glaukos licenses tri-specific biologic for retinal diseases By Investing.com - Investing.com Nigeria
Glaukos licenses retinal biologic RO-104 from RevOpsis Therapeutics - StreetInsider
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases - Yahoo Finance
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus - BioSpace
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance
Glaukos CDO Tomas Navratil sells $251,120 in company stock - Investing.com
Trading-plan sales by Glaukos (GKOS) officer include 888 shares averaging $163.93 each. - Stock Titan
A Look at Glaukos Corp (GKOS) After 6.5% Gain -- GF Value $154.4 - GuruFocus
Glaukos GKOS Jumps As Jefferies Hikes Price Target - Timothy Sykes
Glaukos GKOS Rallies As Jefferies Hikes Price Target - StocksToTrade
Glaukos says late-stage eye disease treatment shows lasting benefits after single dose - Reuters
0.25%
1.68%
大文字化:
|
ボリューム (24 時間):